Past Recipients of the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science

1. **2016 Recipient**  
   **Clara D. Bloomfield, M.D.**  
   Distinguished University Professor, William G. Pace III Professor of Cancer Research  
   Cancer Scholar and Senior Advisor  
   The Ohio State University Comprehensive Cancer Center

2. **2015 Recipient**  
   **Jimmie C. Holland, M.D.**  
   Wayne E. Chapman Chair in Psychiatric Oncology  
   Memorial-Sloan Kettering Cancer Center

3. **2014 Recipient**  
   **Laurie Glimcher, M.D.**  
   President  
   Dana-Farber Cancer Institute

4. **2013 Recipient**  
   **Karen Antman, M.D.**  
   Provost, Boston University Medical Campus  
   Dean, Boston University School of Medicine

5. **2012 Recipient**  
   **Nancy Hopkins, Ph.D.**  
   Amgen, Inc. Professor of Biology  
   Massachusetts Institute of Technology

6. **2011 Recipient**  
   **Edward Benz, M.D.**  
   Professor of Medicine, Pediatrics and Genetics  
   Harvard Medical School

7. **2010 Recipient**  
   **Janet Rowley, M.D. (deceased)**  
   Blum-Riese Distinguished Service Professor of Medicine, of Molecular Genetics and Cell Biology, and of Human Genetics, Section of Hematology/Oncology  
   University of Chicago Medical Center

8. **2009 Recipient**  
   **Margaret Foti, Ph.D., M.D. (h.c.)**  
   CEO, American Association for Cancer Research
2016 Recipient of the Margaret L. Kripke Legend Award

Clara D. Bloomfield, M.D.
Distinguished University Professor
William G. Pace III Professor of Cancer Research
Cancer Scholar and Senior Advisor
The Ohio State University Comprehensive Cancer Center

Dr. Clara D. Bloomfield earned her MD, from the University of Chicago and completed training in internal medicine and medical oncology at the University of Minnesota, where she became a full professor in just 7 years. In 1989, she became professor of medicine and chief of the Division of Oncology at the State University of New York at Buffalo, as well as chair of the Division of Medicine at Roswell Park Cancer Institute. In 1997 she joined The Ohio State University Comprehensive Cancer Center (OSUCCC) as Director. As an elected member of both the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts & Sciences, she is the only female professor at OSU to hold such honors. Currently, Dr. Bloomfield serves as cancer scholar and senior advisor at the OSUCCC. She is also a member of the Leukemia Research Program, a professor of internal medicine, and she holds the William Greenville Pace III Endowed Chair in Cancer Research.

Dr. Bloomfield is an internationally recognized clinical scientist, whose over 40 years of groundbreaking research on adult leukemia and lymphoma—described in more than 1000 publications—have changed the way we think about and treat patients with these diseases. She pioneered the use of biologic characteristics of neoplastic cells for selecting appropriate curative therapy for individual patients. She first suggested and demonstrated that adults, including elderly adults, with acute leukemia could be cured with chemotherapy. She also showed that certain groups of leukemia patients, defined in particular by genetic characteristics of the leukemia, required intensive therapy to be cured, while others could be cured with standard approaches. Her study of chromosomes in leukemia and lymphoma has helped identify genes involved in the development of these diseases, and the application of this information has helped develop effective therapies for individual patients. In particular, she identified several now classic chromosome changes in leukemia and lymphoma, including the Philadelphia chromosome in acute lymphoblastic leukemia and the rearrangement of 16q22 in acute myeloid leukemia. She is considered the world’s authority on how chromosome changes influence treatment and outcomes in adult acute leukemia.

Dr. Bloomfield is the recipient of many prestigious honors, including the 2004 American Association for Cancer Research Joseph H. Burchenal Clinical Research Award, 2006 American Society of Clinical Oncology (ASCO) Distinguished Service Award for Scientific Achievement, the 2008 Henry M. Stratton Medal from the American Society of Hematology, ASCO’s 2009 David A. Karnofsky Memorial Award, and the 2012 Richard L. Schilsky Cancer and Leukemia Group B (CALGB) Achievement Award.

Clara Bloomfield received her award on Thursday, March 24, 2016.
Jimmie C. Holland, M.D.
Wayne E. Chapman Chair in Psychiatric Oncology
Memorial-Sloan Kettering Cancer Center

Jimmie C. Holland, is the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan-Kettering Cancer Center, where she has been since 1977, and professor of Psychiatry at Weill Medical College of Cornell University. Prior to that, she was assistant director of consultation/liaison psychiatry at Albert Einstein College of Medicine and Montefiore Hospital and director of the department of Psychiatry at the E.J. Meyer Memorial Hospital in Buffalo, NY. Dr. Holland has dedicated her entire career to improving the psychological care of patients with cancer and their families. She is credited with establishing psycho-oncology as a subspecialty and created the psychiatric service at Sloan-Kettering, where she also established the nation’s largest training and research program in psycho-oncology. A native Texan raised on a farm, Dr. Holland received her medical degree from Baylor College of Medicine and received her postdoctoral training at St. Louis City Hospital, Malcom Bliss Health Center, Washington University School of Medicine, Massachusetts General Hospital and Harvard University.

Dr. Holland is a member of the Institute of Medicine and a Distinguished Life Fellow of the American Psychiatric Association. She was the 2005 recipient of the American Association for Cancer Research Joseph H. Burchenal Clinical Research Award and, most recently, was inducted into the inaugural class of the AACR Academy of Fellows. She broadened the reach of the field of psycho-oncology internationally as founding president of the International Psycho-Oncology Society. She was also founding president of the American Psychosocial and Behavioral Oncology Society, the first network for multidisciplinary professionals working in supportive aspects of cancer care. Dr. Holland edited the first, and still gold standard, textbook of psycho-oncology, soon to be published in its third edition.

Dr. Holland introduced “Distress Screening” as an essential and required aspect of clinical cancer care, making distress the “6th Vital Sign” currently used as a rapid validated screen for distress; it is increasingly being used in other chronic diseases. She continues to push forward with new innovations that are changing the practice of oncology. Her current clinical focus is on older adults coping with illness where she uses telephone intervention to support housebound elderly patients. The department she founded at Sloan-Kettering remains the largest in the world for clinical care and research in psychological and psychiatric issues. Over 350 professionals in the field trained there.
While distinguishing herself as a pioneer in psychiatry, Dr. Holland also distinguished herself as a strong advocate for advancing the role of women in oncology, especially psycho-oncology. Her trans-generational impact on women is seen in the many current leaders in psycho-oncology, too numerous to name, who either trained with her or sought her counsel. A close colleague of hers provided the following comment: “…there are hundreds of women to whom she has been a beacon, including myself...Her informality and gentleness, coupled with her inextinguishable enthusiasm for new ideas and for the young people she thinks can carry them out, has drawn young women to her like moths to a flame...her support, generosity and example are sufficient to generate careers and change many lives.”

Jimmie Holland received her award on Monday, March 2, 2015.
Laurie H. Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, is President of Dana-Farber Cancer Institute. Before joining Dana-Farber Cancer Institute, she led Weill Cornell and served as Provost for Medical Affairs of Cornell University. She held a Professor of Medicine appointment at the Medical College. Dr. Glimcher was recruited to Weill Cornell in 2012 from Harvard, where she was the Irene Heinz Given Professor of Immunology and Director of the Division of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School, where she headed one of the top immunology programs in the world. She also served as Senior Physician and Rheumatologist at the Brigham and Women’s Hospital.

Dr. Glimcher received her postdoctoral training at Harvard and in the Laboratory of Immunology at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and is board certified in Internal Medicine and Rheumatology. She received her BA degree from Radcliffe College and her MD from Harvard Medical School. As an immunologist, her primary research interests are the biochemical and genetic approaches that elucidate the molecular pathways that regulate CD4 T helper cell development and activation. The complex regulatory pathways governing T helper cell responses are critical for both the development of protective immunity and for the pathophysiologic immune responses underlying autoimmune, infectious and malignant diseases. Dr. Glimcher’s research laboratory has studied the transcriptional pathways that control this important immune checkpoint, leading to many discoveries, including the T-bet and XBP-1 transcription factors, which regulate a variety of immune functions. Most recently, her laboratory has identified new proteins that control osteoblast and osteoclast commitment and activation in skeletal biology with significant implications for diseases of bone, including osteoporosis, osteoarthritis and cancer metastasis to bone.

Dr. Glimcher is the recipient of numerous awards and honors, including the Soma Weiss Award for Undergraduate Research, the Distinguished Young Investigator Award from the American College of Rheumatology, the Leukemia Society’s Stohlman Memorial Scholar Award, the Arthritis Foundation’s Lee S. Howley Award, the FASEB Excellence in Science Award, the American Society of Clinical Investigation Investigator Award, the Klemperer Award, the AAUW Senior Scholar Award, the Huang Meritorious Career Award, the AAI Excellence in Mentoring Award, the Dean’s Award for Leadership in the Advancement of Women Faculty, the American College of Rheumatology Distinguished Investigator Award. In 2012 she received the Ernst W. Bertner Memorial Award, MD Anderson Cancer Center, the William B. Coley Award, Cancer Research Institute, and the Luis Federico Leloir Prize to International Cooperation in Science, Technology and Innovation, Ministry of Health, Argentina.
She is a Fellow of the American Academy of Arts and Sciences, a Member of the Institute of Medicine of the National Academy of Sciences and a Member of the National Academy of Sciences. She is the former President of the American Association of Immunologists. She is a member of the American Asthma Foundation, Health Care Ventures, and the Cancer Research Institute Scientific Advisory Boards. She is on the Board of Trustees of the Memorial Sloan Kettering Cancer Center and the New York Blood Foundation. She is on the Corporate Board of Directors of the Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation.

Dr. Glimcher speaks nationally and internationally on rheumatology, immunology, skeletal biology and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.

Laurie Glimcher received her award on Thursday, March 13, 2014.
2013 Recipient of the Margaret L. Kripke Legend Award

Karen Antman, M.D.
Provost, Boston University Medical Campus
Dean, Boston University School of Medicine

Dr. Karen Antman, an internationally recognized expert on breast cancer, mesotheliomas and sarcomas, previously served as Deputy Director for Translational and Clinical Sciences at the National Cancer Institute of the National Institutes of Health (NIH) and before that as Wu Professor of Medicine and Pharmacology and Director of the Herbert Irving Comprehensive Cancer Center at Columbia University College of Physicians and Surgeons, where she co-directed the cancer care service line at New Your Presbyterian Hospital. She served on the faculty of Harvard Medical School from 1979 to 1993, and had hospital appointments at Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston.

She is a member of the Institute of Medicine and serves on the Administration Board of the American Association of Medical Colleges Council of Deans, and on the board of the Educational Commission for Foreign Medical Graduates. She served on the Council of the Fogarty International Center of the NIH and as President of the American Society of Clinical Oncology, the American Society of Blood and Marrow Transplant, and the American Association for Cancer Research. She has more than 300 publications, edited 5 textbooks and monographs and has published reviews and editorials on medical education, medical policy and the impact of research funding and managed care on clinical research.

Antman received the award at MD Anderson on March 19, 2013.
Nancy Hopkins is the Amgen, Inc. Professor of biology at the Massachusetts Institute of Technology. She is a member of the National Academy of Sciences, a fellow of the American Academy of Arts and Sciences, and a member of the Institute of Medicine of the National Academy. Hopkins obtained a Ph.D. from Harvard University and was a postdoctoral fellow at Harvard and at the Cold Spring Harbor Laboratory. She joined the MIT faculty in 1974. Her lab has worked in three areas: mechanisms of leukemogenesis by mouse RNA tumor viruses; genetics of early vertebrate development using the zebrafish; and use of the zebrafish as a cancer model.

Hopkins became an advocate for women in science after being appointed chair of the first Committee on Women Faculty in the School of Science at MIT in 1995-97. A summary of her committee’s findings was published in 1999 and led to many improvements in the status and number of women faculty at MIT. In 2000 she was appointed to the MIT central administration as co-chair, with then Provost Robert Brown, of the first Council on Faculty Diversity.

Hopkins received the award at MD Anderson on March 22, 2012.
Edward Benz, M.D.
Professor of Medicine, Professor of Pediatrics, Professor of Pathology
Harvard Medical School

Edward J. Benz, Jr., M.D., was selected as the 2011 recipient of MD Anderson's Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science. He is the Professor of Medicine, Pediatrics and Genetics. Benz is a graduate of Princeton University and Harvard Medical School, where his medical school thesis, completed at Children's Hospital, won the Soma Weiss and Leon Resnick Awards for research.

An internationally recognized hematologist, Dr. Benz received his training at Brigham and Women's Hospital, the National Institutes of Health, and the Yale School of Medicine. Board certified in Internal Medicine and Hematology, Dr. Benz is a clinically active internist and expert in inherited anemias and diseases of the red cell.

Dr. Benz has enjoyed a distinguished career in academic internal medicine. He was among the first to apply the emerging technologies of molecular genetics to the study of human disease. His early work, started in medical school, delineated the molecular defects responsible for reduced hemoglobin synthesis in common inherited anemias called the thalassemias. Since that time, he and his laboratory group have made major contributions to our understanding of the molecular basis of hemoglobinopathies; the structure, function and regulation of genes encoding the NaK-ATPase; and, more recently, the biogenesis and molecular pathology of the red cell membrane cytoskeleton. He continues to be an active NIH funded investigator.

Dr. Benz took his first faculty position in the Department of Medicine at Yale where he was appointed Chief of the Division of Hematology in 1987. Immediately prior to assuming the presidency of Dana-Farber, he was the Chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine, one of the most distinguished positions in academic medicine in the United States. Dr. Benz has authored over 300 peer reviewed articles, reviews, chapters and abstracts. He is a co-editor of Hematology: Principles and Practice, widely regarded as one of the major textbooks on hematology published in the United States, the 19th edition of Principles and Practice of Medicine, and the fifth edition of the Oxford Textbook of Medicine for which he and his colleagues received the Royal Society of Authors Textbook Award. He is an associate editor of the New England Journal of Medicine.

Dr. Benz' accomplishments have been recognized by a number of distinctions, including membership in the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Science. He is a past president of the American Society of Hematology, the American Society of Clinical
Investigation and the Association of American Cancer Institutes. In addition to numerous other NIH assignments, he chaired the NIH Director’s Blue Ribbon Panel on the future of Intramural Clinical Research in 2003, co-chaired the NIH Advisory Board for Clinical Research and is currently the chair of the NHLBI working group on Sickle Cell Disease.

“I came to my first faculty job with a salary grant, no start-up package and Ed as a mentor—and that was a pretty good deal!,” writes Nancy Berliner, M.D., chief, division of Hematology, Brigham And Women’s Hospital, Harvard Medical School. “During the past 20 years, his mentorship has been critical to my career trajectory and my academic success.”

“I credit Ed with developing my leadership skills and capabilities, which has shaped my career immensely. When Ed Benz left to become president of Dana-Farber, I was given the title of associate chair of the Department of Medicine. No woman in the past 100 years at Johns Hopkins has ever occupied this position,” states Susan MacDonald, M.D., who continues to hold that title.

In her nomination letter, Gloria Sorensen, Ph.D., faculty vice president for faculty development at Dana-Farber writes: “Dr. Benz is an agent for change in creating an environment where women can flourish and fostering a culture that values the contributions of women.” In 2007, Benz created a Faculty Development office at Dana-Farber and as result of his leadership, the number of women leaders there has increased. Before joining Dana-Farber, he made similar strides at Johns Hopkins.

“Undoubtedly, Dr. Benz’s efforts have played a major role in the rapid increase in the number of women at Johns Hopkins promoted to associate professor and professor over the last 15 years,” states David Hellmann, M.D., chair of Medicine, Johns Hopkins Bayview.

Dr. Benz received his award at MD Anderson on March 24, 2011 and presented a lecture titled “Applying Mentorship, Leadership and Power of Position to Enhancing the Career Development of Women Faculty.”
2010 Recipient of the Margaret L. Kripke Legend Award

Janet Rowley, M.D. (deceased)
Blum-Riese Distinguished Service Professor of Medicine, of Molecular Genetics and Cell Biology, and of Human Genetics, Section of Hematology/Oncology
University of Chicago Medical Center, Chicago, IL

International chromosome expert Janet Rowley, M.D., was selected as the 2010 recipient of MD Anderson’s Margaret L. Kripke Legend Award for Promotion of Women in Cancer Research and Cancer Medicine. Rowley is the Blum-Riese Distinguished Service Professor of Medicine and professor of molecular genetics and cell biology and of human genetics at the University of Chicago Medical Center.

Described as a pioneer, Rowley made a series of remarkable breakthroughs, including the landmark discovery of the first consistent chromosome translocations in any human cancer, the 8:21 translocation in acute myeloid leukemia (AML). Subsequently, she identified a number of recurring translocations in children and adults with leukemia and lymphoma. Her studies of chromosome abnormalities in human leukemia and lymphoma have led to cures for previously untreatable cancers and the development of targeted therapies such as Imatinib (Gleevec) for CML.

In 1998, Rowley was one of three scientists awarded the prestigious Lasker Award and, in 1999, she received the National Medal of Science. In 2005, Rowley received the Landon-AACR Prize for translational research, and, in 2009, she was awarded the Gruber Prize in Genetics and the presidential Medal of Freedom, the United States’ highest civilian honor. In addition to her scientific contributions, she was selected for her dedication to training and mentoring future generations of female scientists, many of whom have become highly successful in their own right.

“Janet Rowley has transformed the fields of cancer and cytogenetics, and, as a result, the field of molecular oncology,” says Elizabeth Travis, Ph.D., associate vice president of Women Faculty Programs, which sponsors the Kripke Legend Award. “Her scientific work has proven immensely influential. She has had a major impact on patient treatment. For more than 40 years, she’s been a dedicated mentor and an excellent role model for women in science and medicine, all while being fully committed to her family, as evidenced as working part-time for 20 years in order to raise her children. I can think of no one who better exemplifies the essence of this award.”

Dr. Rowley received her award at MD Anderson on May 17, 2010.
Dr. Margaret Foti is the inaugural recipient of the Margaret L. Kripke Legend Award. As one of her nominators said, “No one has done more for women in the field of cancer research than Dr. Margaret Foti.” Dr. Foti is a role model and an outstanding example to women in science of what can be achieved by hard work, commitment, and leadership. However, her contribution reaches beyond role model to actively advocating for and making significant changes for women in cancer medicine and science.

She was a driving force behind the Women in Cancer Research within AACR, taking it from an ad hoc group of women to a full council of the AACR fully staffed and with Board access, initiation of the Charlotte Friend Memorial Lecture, she steered the WICR leadership workshops through the AACR Board of Directors, and obtained funding for the program. Dr. Foti supports and advocates for women speakers at all AACR sponsored meetings, and she is adamant that women be nominated for leadership positions, including President.

As another of her nominators said, “Dr. Foti has made a concrete difference in the lives of women in science and is a sterling example of the principles in which Margaret Kripke believes. Her stewardship of women’s careers has spanned decades, brought tangible rewards and touched multiples facets of our lives. She has made a difference in the fight against cancer and is committed to helping other women do the same and give them credit for their endeavors.”

Dr. Margaret Foti received her award at M. D. Anderson Cancer Center on March 25, 2009.